LobbyingAntimicrobial Innovation Alliance lobbying by quarter
Antimicrobial Innovation Alliance's latest lobbying report covers Q4 2025, at under $5,000. Its first report covers Q4 2022; the issues it reports most are Health Issues.
Antimicrobial Innovation Alliance
- Latest quarter
- No record
- Q2 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q2 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
No lobbying spend in this period.
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $0 | 1 |
| Q1 2023 | $0 | 1 |
| Q2 2023 | $0 | 1 |
| Q3 2023 | $0 | 1 |
| Q4 2023 | $0 | 1 |
| Q1 2024 | $0 | 1 |
| Q2 2024 | $0 | 1 |
| Q3 2024 | $0 | 1 |
| Q4 2024 | $0 | 1 |
| Q1 2025 | $0 | 1 |
| Q2 2025 | $0 | 1 |
| Q3 2025 | $0 | 1 |
| Q4 2025 | $0 | 1 |
| Q1 2026 | $0 | 0 |
| Q2 2026 | $0 | 0 |
Policy issues the reports name
- Health issues13 reports
A report that names several issues counts once for each.
Who was lobbied
- HOUSE OF REPRESENTATIVES13 reports
- SENATE13 reports
Firms it paid
| Firm | ||
|---|---|---|
| Forbes-Tate | $0 | 13 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| ELIZABETH GREER | Chief of Staff, Rep. Allen Boyd (2001-2009) | Q1 2023 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 01/19for Q4 2025 | Forbes-Tate | Under $5,000 |
| 25/10/19for Q3 2025 | Forbes-Tate | Under $5,000 |
| 25/07/18for Q2 2025 | Forbes-Tate | Under $5,000 |
| 25/04/18for Q1 2025 | Forbes-Tate | Under $5,000 |
| 25/01/19for Q4 2024 | Forbes-Tate | Under $5,000 |
| 24/10/17for Q3 2024 | Forbes-Tate | Under $5,000 |
| 24/07/13for Q2 2024 | Forbes-Tate | Under $5,000 |
| 24/04/14for Q1 2024 | Forbes-Tate | Under $5,000 |
| 24/01/16for Q4 2023 | Forbes-Tate | Under $5,000 |
| 23/10/18for Q3 2023 | Forbes-Tate | Under $5,000 |
| 23/07/16for Q2 2023 | Forbes-Tate | Under $5,000 |
| 23/04/17for Q1 2023 | Forbes-Tate | Under $5,000 |
| 23/01/15for Q4 2022 | Forbes-Tate | Under $5,000 |